Search Abstracts

Background Only 68% of U.S. men-who-have-sex-with-men (MSM) living with HIV have achieved virologic suppression (VS), sufficiently low to compromise Ending the HIV Epidemic goals. Objective monitoring of antiretroviral therapy (ART) adherence via drug-level testing can inform interventions. A rapid, low-cost urine point-of-care (POC) tenofovir (TFV) assay has been developed by our group as an objective…

Background The SEARCH dynamic choice HIV prevention (DCP) intervention, including structured choice of biomedical prevention modality (oral PrEP, PEP, Cab-LA) with option to switch over time, increased time covered by biomedical prevention and reduced HIV incidence among men and women in randomized trials in Kenya and Uganda. We use HIV Synthesis, an existing individual-based HIV…

Background Differentiated service delivery (DSD) models have reduced strain on health services and improved client experience, retention and viral suppression, but little is known about the impact of HIV DSD models on quality of life (QoL), which is essential for optimizing person-centered care. This study assessed the impact of DSD models on QoL, loss to follow-up (LTFU), and mortality among persons living with…

Background Emergency Departments (EDs) are a major source of medical care for people living with HIV (PLWH) in the United States. PLWH who are out of care (OOC) experience poorer health outcomes and contribute to more than 40% of HIV transmissions. Gilead Sciences’ FOCUS program is a public health initiative that supports healthcare institutions to implement…

Background People who inject drugs (PWID) in the US have high HIV incidence and fatal overdose rates, yet uptake is low for pre-exposure prophylaxis (PrEP; 1%) and medications for opioid use disorder (MOUD; 18%). Long-acting PrEP and MOUD formulations may improve uptake and adherence. Methods Using the validated MYRIAD multimorbidity microsimulation model (accounting for impact…

Background On 9th February, 2024, Zambia launched the use of Cabotegravir Long-Acting (CAB-LA) for HIV prevention, as an additional layer to oral PrEP   The aim was to expand HIV prevention options for high-risk individuals and address challenges with oral PrEP such as inconsistent use due to pill burden, privacy issues and stigma. However, within 6…

Background Cabotegravir/rilpivirine (CAB/RPV), the first complete long-acting injectable (LAI) antiretroviral therapy (ART) regimen, was approved by the FDA in January 2021 and offers a convenient monthly to bimonthly alternative to daily oral ART with the potential to improve adherence and viral suppression. To understand the degree of uptake of CAB/RPV, we assessed trends of and characteristics…

Background Only 23% of people living with HIV (PLWH) in rural Uganda are virally suppressed, which falls far short of the 95% suppression target set by UNAIDS. This illustrates the need for tailored strategies to engage PLWH in rural settings and retain them in care. Traditional healers (TH) are often the first point of contact…

Background With advances in HIV prevention, understanding factors that promote uptake of novel PrEP agents, including social networks, could be critical to increasing coverage and interrupting HIV transmission in vulnerable populations, such as men who have sex with men (MSM). Methods We conducted a network-based online survey among MSM and transgender women (TGW) in Baltimore,…

Background Daily and on-demand oral pre-exposure prophylaxis (PrEP) have been shown to be effective at preventing HIV acquisition among cisgender men and transgender women, but only daily PrEP is recommended for cisgender women. On-demand PrEP may be a valuable option to improve PrEP uptake, effective use, and persistence in cisgender women. We use data from…